Tuesday’s Top Biotech Stories: Johnson & Johnson, Roche, Novartis, Google

Johnson & Johnson, Roche, Novartis, Google are the top stocks to watch in health care this Tuesday morning.

Jul 15, 2014 at 8:56AM


Let's take a look at four stocks -- Johnson & Johnson (NYSE:JNJ), Roche (NASDAQOTH:RHHBY), Novartis (NYSE:NVS), and Google (NASDAQ:GOOG) (NASDAQ:GOOGL)-- which could all loom large in health care headlines this Tuesday morning.

J&J tops expectations during the second quarter
Johnson & Johnson just reported its second quarter earnings. The diversified medical giant's adjusted diluted earnings climbed 12.2% year-over-year to $1.66 per share, topping the consensus estimate by $0.11. Revenue rose 9.1% year-over-year to $19.5 billion, also beating estimates by $550 million.

Out of J&J's three main business segments, Pharmaceuticals was the standout performer, posting a 21.1% year-over-year jump in revenue to $8.5 billion, thanks to strong sales of newer drugs like Olysio (hepatitis C), Xarelto (blood thinner), Zytiga (prostate cancer), Invokana (diabetes), and Imbruvica (leukemia and lymphoma). Revenue at Medical Devices and Diagnostics inched up 0.7% to $7.2 billion, while revenue at its Consumer Sales segment rose 2.4% to $3.7 billion. J&J also raised its full year EPS guidance (excluding special items) from $5.80-$5.90 to $5.85-$5.92.

Shares of J&J, which are already up 17% over the past 12 months, remain relatively unchanged in pre-market trading following the announcement.

Roche's Avastin plus chemo gets a priority review for cervical cancer
The FDA has just granted a priority review to Roche's Avastin plus chemotherapy as a treatment for persistent, recurrent, or metastatic cervical cancer.

The designation was made based on data from a National Cancer Institute-sponsored 452-patient phase 3 study that evaluated the safety and efficacy of the combination. Median overall survival improved from 13.3 months to 17.0 months when compared to chemotherapy alone. Median progression-free survival improved from 5.9 months to 8.2 months.

Avastin is already approved for colorectal, lung, kidney, and brain cancers. Avastin is also frequently used as an off-label treatment for two eye conditions -- wet age-related macular edema (AMD) and diabetic macular edema (DME) -- which are both frequently treated with Novartis/Roche's Lucentis.

Last year, Roche reported 6.25 billion CHF ($7 billion) in Avastin sales, which accounted for 13% of its top line.

Novartis licenses Google's "smart lens" and announces new Alzheimer's plans
Novartis has just made two key announcements -- that its Alcon eye care division signed an agreement with Google to license its "smart lens" technology for ocular medical uses, and that it plans to test new drugs for Alzheimer's disease.

Google previously showcased its "smart lens" technology as an experimental smart contact lens which attempts to read glucose levels from tears. Google had been previously testing the lens' ability to wirelessly synchronize with a mobile device, in a similar manner as wireless glucose meters like Johnson & Johnson's OneTouch Verio Sync Meter.

However, Alcon intends to develop the technology further for eye care uses, with the ultimate goal of disease mapping and prevention. The financial terms of the deal were not disclosed. Alcon, which Novartis acquired between 2008 and 2011, sells prescription and over-the-counter eye care products, contact lenses, and surgical products. Last year, the division posted sales of $10.5 billion, accounting for 18% of Novartis' annual revenue.

For Google, the Novartis deal further extends its reach into health care, which already includes its biotech subsidiary Calico, Google Fit for mobile fitness, Google Glass applications in hospitals, and Google Helpouts as a telehealth platform. 

In regards to Alzheimer's disease, Novartis plans to test two experimental drugs on symptomless patients with a genetic risk of developing the disease. Both therapies aim to attack the amyloid proteins that may be linked to the disease. However, prior attempts from a number of companies to reduce beta amyloids in patients with symptoms have been largely unsuccessful or inconclusive in reducing symptoms.

1 more top stock opportunity to watch today
The best investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool’s new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.


Leo Sun owns shares of Roche and Google (C shares). The Motley Fool recommends Google (A shares), Google (C shares), and Johnson & Johnson. The Motley Fool owns shares of Google (A shares), Google (C shares), and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information